Delay and Pay? Healthcare Costs Associated with Late Oral Anti-coagulant Prescribing in People with Atrial Fibrillation.
Ryan J MulhollandGiorgio CiminataTerry J QuinnKevin G PollockSteven ListerClaudia GeuePublished in: PharmacoEconomics (2024)
AF is associated with significant healthcare resource utilisation and costs, particularly in the context of delayed or non-initiation of anti-coagulation. Indeed, there exists substantial opportunity to improve the utilisation and prompt initiation in people newly diagnosed with AF in Scotland. Interventions to mitigate against the growing economic burden of AF should focus on reducing admissions to hospitals and care homes, which are the principal drivers of costs; prescriptions and outpatient appointments account for a relatively small proportion of overall costs for AF.
Keyphrases
- atrial fibrillation
- healthcare
- newly diagnosed
- oral anticoagulants
- catheter ablation
- left atrial
- left atrial appendage
- direct oral anticoagulants
- primary care
- heart failure
- percutaneous coronary intervention
- palliative care
- health insurance
- affordable care act
- pain management
- chronic pain
- acute coronary syndrome
- coronary artery disease
- health information
- drug induced